Sonoma Pharmaceuticals, Inc. announced its financial results for fiscal year 2025 and the fourth quarter ended March 31, 2025, on June 17, 2025. The company reported a 12% increase in total revenue for FY 2025, reaching $14.29 million, up from $12.74 million in FY 2024.
For the fourth quarter of 2025, revenues increased by 9% compared to the fourth quarter of 2024. The net loss for FY 2025 improved significantly, decreasing by 29% to $3.46 million from $4.83 million in FY 2024.
The EBITDA loss also showed substantial improvement, decreasing by 17% for the full fiscal year 2025 compared to FY 2024, and by 59% for the fourth quarter of 2025 compared to the prior year's fourth quarter. These results indicate continued revenue growth and consistent progress towards profitability.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.